GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MedMira Inc (OTCPK:MMIRF) » Definitions » Gross Profit

MedMira (MedMira) Gross Profit : $0.19 Mil (TTM As of Jan. 2024)


View and export this data going back to . Start your Free Trial

What is MedMira Gross Profit?

MedMira's gross profit for the three months ended in Jan. 2024 was $0.05 Mil. MedMira's gross profit for the trailing twelve months (TTM) ended in Jan. 2024 was $0.19 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. MedMira's gross profit for the three months ended in Jan. 2024 was $0.05 Mil. MedMira's Revenue for the three months ended in Jan. 2024 was $0.11 Mil. Therefore, MedMira's Gross Margin % for the quarter that ended in Jan. 2024 was 45.95%.

MedMira had a gross margin of 45.95% for the quarter that ended in Jan. 2024 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of MedMira was 80.32%. The lowest was 29.12%. And the median was 63.12%.

Warning Sign:

MedMira Inc gross margin has been in long-term decline. The average rate of decline per year is -8.5%.


MedMira Gross Profit Historical Data

The historical data trend for MedMira's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedMira Gross Profit Chart

MedMira Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.32 0.42 1.37 0.24 0.23

MedMira Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.05 0.04 0.05 0.05

Competitive Comparison of MedMira's Gross Profit

For the Biotechnology subindustry, MedMira's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MedMira's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MedMira's Gross Profit distribution charts can be found below:

* The bar in red indicates where MedMira's Gross Profit falls into.



MedMira Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

MedMira's Gross Profit for the fiscal year that ended in Jul. 2023 is calculated as

Gross Profit (A: Jul. 2023 )=Revenue - Cost of Goods Sold
=0.328 - 0.101
=0.23

MedMira's Gross Profit for the quarter that ended in Jan. 2024 is calculated as

Gross Profit (Q: Jan. 2024 )=Revenue - Cost of Goods Sold
=0.111 - 0.06
=0.05

Gross Profit for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.19 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

MedMira's Gross Margin % for the quarter that ended in Jan. 2024 is calculated as

Gross Margin % (Q: Jan. 2024 )=Gross Profit (Q: Jan. 2024 ) / Revenue (Q: Jan. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.05 / 0.111
=45.95 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


MedMira  (OTCPK:MMIRF) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

MedMira had a gross margin of 45.95% for the quarter that ended in Jan. 2024 => Durable competitive advantage


MedMira Gross Profit Related Terms

Thank you for viewing the detailed overview of MedMira's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


MedMira (MedMira) Business Description

Traded in Other Exchanges
Address
155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3
MedMira Inc is a biotechnology company that is engaged in the business of research, development, and manufacturing of rapid diagnostics and technologies. The company has one reportable operating segment, rapid diagnostic products and services. The product line of the company includes RevealHIV which detects antibodies to HIV-1 and HIV-2 in whole blood, serum or plasma; H Pylori which detects antibodies in serum, plasma, and whole blood; syphilis which detects treponema pallidum antibodies in serum, plasma, and whole blood; among other products. The company generates revenue geographically from North America, Europe, Asia pacific. The majority of the revenue is generated from North America.

MedMira (MedMira) Headlines

From GuruFocus

Progress Update on MedMira's COVID-19 Product Family

By GlobeNewswire GlobeNewswire 01-30-2021

Management Cease Trade Order Update

By GlobeNewswire GlobeNewswire 12-26-2018

MedMira Announces Product Update

By GlobeNewswire GlobeNewswire 12-31-2020

MedMira Reports Second Quarter Results

By GlobeNewswire GlobeNewswire 03-30-2018

MedMira Reports First Quarter Results FY2020

By GlobeNewswire GlobeNewswire 12-31-2019

MedMira Reports First Quarter Results FY2022

By GlobeNewswire GlobeNewswire 12-31-2021

MedMira Introduces VYRA TriDemic

By ACCESSWIRE ACCESSWIRE 12-30-2022

MedMira Reports Third Quarter Results

By GlobeNewswire GlobeNewswire 06-30-2018